These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1126604)

  • 1. Jaundice due to erythromycin estolate.
    Lunzer MR; Huang SN; Ward KM; Sherlock S
    Gastroenterology; 1975 May; 68(5 Pt 1):1284-91. PubMed ID: 1126604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythromycin jaundice: diagnosis by an in vitro challenge test.
    Cooksley WG; Powell LW
    Aust N Z J Med; 1977 Jun; 7(3):291-3. PubMed ID: 269690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete biliary obstruction due to erythromycin estolate administration in an infant.
    Krowchuk D; Seashore JH
    Pediatrics; 1979 Dec; 64(6):956-8. PubMed ID: 514726
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hepatocellular jaundice due to erythromycin estolate].
    Zlotnick A
    Harefuah; 1978 Aug; 95(3-4):127-8. PubMed ID: 700498
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythromycin estolate and jaundice.
    Inman WH; Rawson NS
    Br Med J (Clin Res Ed); 1983 Jun; 286(6382):1954-5. PubMed ID: 6407653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases.
    Zafrani ES; Ishak KG; Rudzki C
    Dig Dis Sci; 1979 May; 24(5):385-96. PubMed ID: 456225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of beta hemolytic streptococcal pharyngitis. Comparison of amoxicillin, erythromycin estolate, and penicillin V.
    Breese BB; Disney FA; Green JL; Talpey WB
    Clin Pediatr (Phila); 1977 May; 16(5):460-3. PubMed ID: 403044
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of group A streptococcal pharyngitis: a randomized controlled study of twice-daily erythromycin ethylsuccinate versus erythromycin estolate.
    Ginsburg CM; McCracken GH; Steinberg JB; Crow SD; Dildy BF; Lancaster K; Olsen K
    Pediatr Infect Dis; 1982; 1(6):384-7. PubMed ID: 6761656
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythromycin estolate-induced hepatitis. Ultrastructural study of liver.
    Gafter U; Mandel EM; Weiss S; Djaldetti M
    N Y State J Med; 1979 Jan; 79(1):87-9. PubMed ID: 282477
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythromycin therapy for group A streptococcal pharyngitis. Results of a comparative study of the estolate and ethylsuccinate formulations.
    Ginsburg CM; McCracken GH; Crow SD; Dildy BR; Morchower G; Steinberg JB; Lancaster K
    Am J Dis Child; 1984 Jun; 138(6):536-9. PubMed ID: 6372437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatitis caused by various derivatives of erythromycin].
    Funck-Brentano C; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1983 Apr; 7(4):362-9. PubMed ID: 6347792
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythromycin estolate to remain on market.
    FDA Drug Bull; 1982 Aug; 12(2):14. PubMed ID: 7141171
    [No Abstract]   [Full Text] [Related]  

  • 13. [Alterations in liver function produced by erythromycin estolate in isolated and perfused rat liver].
    Adinolfi L; Gaeta GB; Utili R
    Boll Soc Ital Biol Sper; 1980 Aug; 56(16):1621-5. PubMed ID: 7459082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
    Keeffe EB; Reis TC; Berland JE
    Dig Dis Sci; 1982 Aug; 27(8):701-4. PubMed ID: 6980110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Streptococcal pharyngitis therapy. A comparison of two erythromycin formulations.
    Derrick CW; Dillon HC
    Am J Dis Child; 1979 Nov; 133(11):1146-8. PubMed ID: 389036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythromycin therapy for streptococcal pharyngitis.
    Derrick CW; Dillon HC
    Am J Dis Child; 1976 Feb; 130(2):175-8. PubMed ID: 766615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of inclusion conjunctivitis after oral erythromycin therapy.
    Laperrière H; Lefebvre J
    CMAJ; 1988 Nov; 139(9):875. PubMed ID: 3179892
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cholestatic hepatitis caused by erythromycin estolate].
    García Monzón C; Noguerado A; Hidalgo S; Escudero V
    Rev Clin Esp; 1985 Nov; 177(8):420-1. PubMed ID: 3836470
    [No Abstract]   [Full Text] [Related]  

  • 19. [Controlled study of the liver-protective effect of cycloxilic acid in a form of iatrogenic liver disease].
    Neuman M; Fluteau G
    Clin Ter; 1978 Nov; 87(3):243-64. PubMed ID: 380876
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA begins proceedings to remove erythromycin estolate from market.
    FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.